Immunicum meddelar lovande resultat avseende överlevnad i fas II-studien MERECA med ilixadencel i njurcancer
February 22, 2021 02:00 ET
|
Immunicum AB
Pressmeddelande 22 februari 2021 Immunicum meddelar lovande resultat avseende överlevnad i fas II-studien MERECA med ilixadencel i njurcancer - Medianöverlevnad för patientgruppen som behandlades...
Immunicum Announces Encouraging Signs of Survival Benefit in Phase II MERECA Trial of Ilixadencel in Kidney Cancer
February 22, 2021 02:00 ET
|
Immunicum AB
Press Release 22 February 2021 Immunicum Announces Encouraging Signs of Survival Benefit in Phase II MERECA Trial of Ilixadencel in Kidney Cancer -- Median Overall Survival (OS) for the...